Java Treeview–extensible visualization of microarray data.
In PLoS ONE, 2003
... purchased a recombinant murine EphA2-Fc chimera (R&D Systems, Minneapolis, MN), polyclonal antibodies derived in rabbits against EphA2 and EFNA1 (Santa Cruz Biotechnologies, Santa Cruz, CA), a horseradish peroxidase–linked anti-mouse and ant-rabbit secondary antibodies (Cell Signaling Biotechnology, Beverly, MA), and ...
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Budapest, Hungary. In Curr Cancer Drug Targets, 2014
These include HER2 amplification, impaired access to the binding site (p95HER2, Δ16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcγR), and altered miRNA expression signatures.
Clinical impact of hepatitis B and C virus envelope glycoproteins.
Vandœuvre-lès-Nancy, France. In World J Gastroenterol, 2013
HCV entry is a complex multistep process involving multiple cell cofactors (glycosaminoglycans, low density lipoprotein receptor, SR-B1, CD81, claudin-1, occludin, EGFR, EphA2) in the interaction with HCV E1/E2 envelope glycoproteins.
Tumour virology. Entry requirements.
In Nat Rev Cancer, 2012
Two papers show that EPHA2 is a receptor for Kaposi's sarcoma-associated herpesvirus (KSHV) and is required for KSHV infection of endothelial cells.